Ahmed Alaysereen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ahmed Alaysereen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Hussain
School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain (RCSI-Bahrain), Busaiteen P.O. Box 15503, Bahrain
1 shared publication - Abdulrahman Al-Majmuei
Medicine, Royal College of Surgeons in Ireland, Manama, BHR
1 shared publication - Ahmed J. AlAraibi
School of Medicine, The Royal College of Surgeons in Ireland, Medical University of Bahrain, Busaiteen P.O. Box 15503
1 shared publication - G. Roshan Deen
Materials for Medicine Research Group, School of Medicine, Royal College of Surgeons in Ireland (RCSI), Medical University of Bahrain, Busaiteen 228, Bahrain
1 shared publication - Mohammad Alatoom
Department of Surgery, School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain (RCSI-MUB), Busaiteen, Bahrain
1 shared publication - Yahya Waly
Materials for Medicine Research Group, School of Medicine, Royal College of Surgeons in Ireland, Medical University of Bahrain, Busaiteen 228, Bahrain
1 shared publication
Latest Publications
- Open Access
- 3 January 2026
- Published by MDPI AG in Biosensors
- Vol. 16 (1) , 39
Evolution of Biosensors and Current State-of-the-Art Applications in Diabetes Control
Diabetes is a chronic metabolic disorder that poses a growing global health challenge, currently affecting nearly 500 million people. Over the past four decades, the rising prevalence of diabetes has highlighted the urgent need for innovations in monitoring and management. Traditional enzymatic methods, including those using glucose oxidase, glucose dehydrogenase, and hexokinase, are widely adopted due to their specificity and relative ease of use. However, they are hindered by issues of instability, environmental sensitivity, and interference from other biomolecules. Non-enzymatic sensors, which employ metals and nanomaterials for the direct oxidation of glucose, offer an attractive alternative. These platforms demonstrate higher sensitivity and cost-effectiveness, though they remain under refinement for routine use. Non-invasive glucose detection represents a futuristic leap in diabetes care. By leveraging alternative biofluids such as saliva, tears, sweat, and breath, these methods promise enhanced patient comfort and compliance. Nonetheless, their limited sensitivity continues to challenge widespread adoption. Looking forward, the integration of nanotechnology, wearable biosensors, and artificial intelligence paves the way for personalized, affordable, and patient-centered diabetes management, marking a transformative era in healthcare. This review explores the evolution of glucose monitoring, from early chemical assays to advanced state-of-the-art nanotechnology-based approaches.
- 3 January 2026
- Published by MDPI AG in Biosensors
- Vol. 16 (1) , 39
Open AccessEvolution of Biosensors and Current State-of-the-Art Applications in Diabetes Control
Diabetes is a chronic metabolic disorder that poses a growing global health challenge, currently affecting nearly 500 million people. Over the past four decades, the rising prevalence of diabetes has highlighted the urgent need for innovations in monitoring and management. Traditional enzymatic methods, including those using glucose oxidase, glucose dehydrogenase, and hexokinase, are widely adopted due to their specificity and relative ease of use. However, they are hindered by issues of instability, environmental sensitivity, and interference from other biomolecules. Non-enzymatic sensors, which employ metals and nanomaterials for the direct oxidation of glucose, offer an attractive alternative. These platforms demonstrate higher sensitivity and cost-effectiveness, though they remain under refinement for routine use. Non-invasive glucose detection represents a futuristic leap in diabetes care. By leveraging alternative biofluids such as saliva, tears, sweat, and breath, these methods promise enhanced patient comfort and compliance. Nonetheless, their limited sensitivity continues to challenge widespread adoption. Looking forward, the integration of nanotechnology, wearable biosensors, and artificial intelligence paves the way for personalized, affordable, and patient-centered diabetes management, marking a transformative era in healthcare. This review explores the evolution of glucose monitoring, from early chemical assays to advanced state-of-the-art nanotechnology-based approaches.